Abstract Number: L06 • ACR Convergence 2023
Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is an inflammatory, fibrotic, and vasculopathic disease that causes severe multi-organ dysfunction leading to significant morbidity and early mortality.When patients…Abstract Number: L19 • ACR Convergence 2023
A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…Abstract Number: 0166 • ACR Convergence 2023
Annual Economic Burden for Patients with Familial Hypophosphatemia in the United States
Background/Purpose: Familial hypophosphatemia (FH) is most commonly due to phosphate regulating endopeptidase X-linked (PHEX) gene mutations resulting in renal phosphate wasting, which leads to rickets,…Abstract Number: 0441 • ACR Convergence 2023
Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Background/Purpose: Ongoing debate exists regarding the optimal sequence of tumor necrosis factor inhibitors and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) as…Abstract Number: 1006 • ACR Convergence 2023
Use of Implementation Strategies to Promote Adherence of Knee Osteoarthritis Guidelines and Improve Patient Outcomes: A Systematic Review
Background/Purpose: Despite the development of care models and practice guidelines the translation of knee osteoarthritis guidelines to practice remains suboptimal. Theoretically informed implementation strategies may…Abstract Number: 1264 • ACR Convergence 2023
Nomination of Biomarkers for Self-testing Disease Activity in Rheumatoid Arthritis Using Patient Similarity Networks: A Pilot Study
Background/Purpose: Although telemedicine in rheumatoid arthritis (RA) could improve disease control with lower healthcare costs, knowledge of suitable parameters for self-testing disease activity still remains…Abstract Number: 1515 • ACR Convergence 2023
Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis
Background/Purpose: Revised CRISS has been proposed an approvable outcome measure in early diffuse cutaneous SSc (dcSSc)1. The index is undergoing the FDA review as part…Abstract Number: 1901 • ACR Convergence 2023
Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? – Results from the EuroSpA Collaboration
Background/Purpose: When assessing disease activity in patients with axial spondyloarthritis (axSpA), the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) is recommended over ASDAS…Abstract Number: 2262 • ACR Convergence 2023
Identifying Important Domains for Inclusion in a Novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): Results of a Modified Delphi Study
Background/Purpose: The Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE) is a novel clinical outcome assessment (COA) for SLE randomized controlled trials (RCTs), being developed…Abstract Number: 2522 • ACR Convergence 2023
Diabetes Mellitus Impacts Primary Total Hip Arthroplasty Outcomes: A National Cohort Study
Background/Purpose: Primary total hip arthroplasty (THA) patients often have concomitant medical comorbidities. This study aims to identify the impact of diabetes mellitus (DM) on inpatient…Abstract Number: 0176 • ACR Convergence 2023
Impact of Social Determinants of Health Factors on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Background/Purpose: Social determinants of health (SDOH) have a significant impact on the health outcomes of many chronic conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…Abstract Number: 0482 • ACR Convergence 2023
Preference and Relative Sensitivity of Indicators Reporting Response Rate in Pharmaceutical Trials of Psoriasis and Psoriatic Arthritis
Background/Purpose: Numerous indicators have been proposed to evaluate the efficacy for randomized clinical trials (RCTs) of psoriasis (Pso) and psoriatic arthritis (PsA), but the comparability…Abstract Number: 1020 • ACR Convergence 2023
An Increase in Safety Outcome Trials and the Issue of Informed Consent
Background/Purpose: The randomized controlled trial (RCT remains a most important research tool and a necessary document for drug licensing. Informed consent is an integral component…Abstract Number: 1286 • ACR Convergence 2023
Impact of Body Mass Index (BMI) on Upper versus Lower Extremity Joints Assessed Using Clinical and Musculoskeletal Ultrasound Measures in Rheumatoid Arthritis Patients
Background/Purpose: Tender and swollen joints counts may be differentially affected in rheumatoid arthritis (RA) patients with obesity. A prior study demonstrated an association between increased…Abstract Number: 1552 • ACR Convergence 2023
Epidemiology and Outcome of Eosinophilic Granulomatosis with Polyangiitis in France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss) belongs to the group of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). There are no recent data on…
- 1
- 2
- 3
- …
- 40
- Next Page »